Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation.


Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
02 2019
Historique:
received: 27 11 2017
accepted: 15 05 2018
revised: 09 04 2018
pubmed: 16 6 2018
medline: 25 2 2020
entrez: 16 6 2018
Statut: ppublish

Résumé

Relapse of haematological malignancies after allogeneic haematopoietic stem cell transplant is a major cause of mortality. The immunological mechanisms that may lead to disease relapse may include immunological immaturity prior to reconstitution of the allogeneic immune system, tumour antigen downregulation or promotion of T-cell exhaustion by interactions with the tumour microenvironment. Current therapeutic strategies for post-transplant relapse are limited in their efficacy and alternative approaches are required. In this review, we discuss the mechanisms of T and NK-cell immune evasion that facilitate relapse of haematological malignancies after allogeneic stem cell transplantation, and explore emerging strategies to augment the allogeneic immune system in order to construct a more potent graft versus tumour response.

Identifiants

pubmed: 29904127
doi: 10.1038/s41409-018-0244-z
pii: 10.1038/s41409-018-0244-z
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-189

Auteurs

Eric Wong (E)

Clinical Haematology and Bone Marrow Transplantation, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Victoria, Australia. eric.wong@mh.org.au.
Australian Cancer Research Foundation Translational Research Laboratory, Victoria, Australia. eric.wong@mh.org.au.
Department of Medicine, University of Melbourne, Victoria, Australia. eric.wong@mh.org.au.

Joanne E Davis (JE)

Australian Cancer Research Foundation Translational Research Laboratory, Victoria, Australia.
Department of Medicine, University of Melbourne, Victoria, Australia.

Andrew Grigg (A)

Department of Medicine, University of Melbourne, Victoria, Australia.
Department of Clinical Haematology and Olivia Newton John Cancer Research Institute, Austin Hospital, Victoria, Australia.

Jeff Szer (J)

Clinical Haematology and Bone Marrow Transplantation, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Victoria, Australia.
Department of Medicine, University of Melbourne, Victoria, Australia.

David Ritchie (D)

Clinical Haematology and Bone Marrow Transplantation, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Victoria, Australia.
Australian Cancer Research Foundation Translational Research Laboratory, Victoria, Australia.
Department of Medicine, University of Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH